BIOCYTO LIMITED

BioCyto Limited is a pre‑clinical stage biopharmaceutical company dedicated to advancing therapeutic delivery through innovative nanotechnology. By designing biocompatible intranasal and injectable drug‑delivery systems, BioCyto enhances the pharmacological properties of a wide range of therapeutics, enabling sustained release and preventing dose dumping.

The company’s core expertise lies in three complementary platforms. Its electrospraying technology produces solid bead or core‑shell nanoparticles that can encapsulate unstable bioactives, improve dissolution of poorly water‑soluble drugs and facilitate selective transport across biological barriers such as the blood‑brain barrier and the gastrointestinal tract. Smart polymers form the second pillar, offering low‑density carriers with large internal payload spaces, functionalised coatings and cross‑linker ligands for targeted, controlled delivery—including ophthalmic applications. Finally, BioCyto’s controlled‑release systems employ rationally designed chemical linkers and biodegradable materials to provide precise, predictable release rates at the desired site and time within the body.

Through these versatile nanocarrier platforms, BioCyto serves drug developers seeking to augment formulation performance, improve safety profiles and expand the therapeutic potential of their candidates.